Opus Genetics Aligns with FDA on Phase 3 Trial Design for OPGx-LCA5 in Inherited Retinal Disease
July 6, 2026 — Opus Genetics announced that it has reached alignment with the U.S. Food and Drug Administration on the design of its registrational Phase 3 clinical trial evaluating OPGx-LCA5 for…
Read the full articleYou might also wanna read
Apertura Enters CRADA with NIH Institutes to Evaluate BBB-Crossing AAV Capsid for NPC1 Gene Therapy
PackGene Biotech·1d ago
Atsena Selects Lead Candidate for Dual-Vector AAV Gene Therapy Program in Stargardt Disease
PackGene Biotech·1d ago
Allotera Therapeutics Raises Additional $35M to Advance Off-the-Shelf CAR-T Therapy for T-Cell Cancers
PackGene Biotech·2d ago
Genespire Reports Preclinical Data Supporting Immune-Shielded Lentiviral Gene Therapy for MMA
PackGene Biotech·2d ago
Engineered AAV5 Vectors Use Glymphatic Delivery to Target Human Glial Cells Across the Brain
PackGene Biotech·2d ago
Epicrispr Completes Dose Escalation in First-in-Human AAV Gene Therapy Trial for FSHD
PackGene Biotech·3d ago
Comments
Sign in to join the conversation.
No comments yet. Be the first.